Published in Clin Rheumatol on November 09, 2011
Extracellular acidosis is a novel danger signal alerting innate immunity via the NLRP3 inflammasome. J Biol Chem (2013) 1.31
Mechanistic aspects of inflammation and clinical management of inflammation in acute gouty arthritis. J Clin Rheumatol (2013) 1.07
Role of the NLRP3 inflammasome in the transient release of IL-1β induced by monosodium urate crystals in human fibroblast-like synoviocytes. J Inflamm (Lond) (2015) 0.84
Gout: An old disease in new perspective - A review. J Adv Res (2017) 0.78
Effects of RuPeng15 Powder (RPP15) on Monosodium Urate Crystal-Induced Gouty Arthritis in Rats. Evid Based Complement Alternat Med (2015) 0.77
Therapeutic Effect of Total Saponins from Dioscorea nipponica Makino on Gouty Arthritis Based on the NF-κB Signal Pathway: An In vitro Study. Pharmacogn Mag (2016) 0.75
Gadolinium-enhanced MRI features of acute gouty arthritis on top of chronic gouty involvement in different joints. Clin Rheumatol (2015) 0.75
Gout-associated uric acid crystals activate the NALP3 inflammasome. Nature (2006) 24.43
Estimates of the prevalence of arthritis and other rheumatic conditions in the United States. Part II. Arthritis Rheum (2008) 19.80
Molecular identification of a danger signal that alerts the immune system to dying cells. Nature (2003) 8.90
Febuxostat compared with allopurinol in patients with hyperuricemia and gout. N Engl J Med (2005) 7.24
Purine-rich foods, dairy and protein intake, and the risk of gout in men. N Engl J Med (2004) 6.53
EULAR evidence based recommendations for gout. Part II: Management. Report of a task force of the EULAR Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT). Ann Rheum Dis (2006) 6.36
A pilot study of IL-1 inhibition by anakinra in acute gout. Arthritis Res Ther (2007) 4.65
Pathogenesis of gout. Ann Intern Med (2005) 4.50
Alcohol intake and risk of incident gout in men: a prospective study. Lancet (2004) 4.12
High versus low dosing of oral colchicine for early acute gout flare: Twenty-four-hour outcome of the first multicenter, randomized, double-blind, placebo-controlled, parallel-group, dose-comparison colchicine study. Arthritis Rheum (2010) 4.00
British Society for Rheumatology and British Health Professionals in Rheumatology guideline for the management of gout. Rheumatology (Oxford) (2007) 3.39
Effects of febuxostat versus allopurinol and placebo in reducing serum urate in subjects with hyperuricemia and gout: a 28-week, phase III, randomized, double-blind, parallel-group trial. Arthritis Rheum (2008) 3.25
Increasing prevalence of gout and hyperuricemia over 10 years among older adults in a managed care population. J Rheumatol (2004) 3.17
Reduction of plasma urate levels following treatment with multiple doses of pegloticase (polyethylene glycol-conjugated uricase) in patients with treatment-failure gout: results of a phase II randomized study. Arthritis Rheum (2008) 2.61
Prevalence of contraindications and prescription of pharmacologic therapies for gout. Am J Med (2011) 2.57
Risk of serious infections during rituximab, abatacept and anakinra treatments for rheumatoid arthritis: meta-analyses of randomised placebo-controlled trials. Ann Rheum Dis (2008) 2.33
The interleukin 1 inhibitor rilonacept in treatment of chronic gouty arthritis: results of a placebo-controlled, monosequence crossover, non-randomised, single-blind pilot study. Ann Rheum Dis (2009) 2.29
The association between gout and nephrolithiasis: the National Health and Nutrition Examination Survey III, 1988-1994. Am J Kidney Dis (2002) 2.26
The urate-lowering efficacy and safety of febuxostat in the treatment of the hyperuricemia of gout: the CONFIRMS trial. Arthritis Res Ther (2010) 2.07
Canakinumab for the treatment of acute flares in difficult-to-treat gouty arthritis: Results of a multicenter, phase II, dose-ranging study. Arthritis Rheum (2010) 2.00
Febuxostat, a novel nonpurine selective inhibitor of xanthine oxidase: a twenty-eight-day, multicenter, phase II, randomized, double-blind, placebo-controlled, dose-response clinical trial examining safety and efficacy in patients with gout. Arthritis Rheum (2005) 1.70
Hyperalgesia, synovitis and multiple biomarkers of inflammation are suppressed by interleukin 1 inhibition in a novel animal model of gouty arthritis. Ann Rheum Dis (2009) 1.64
TNF-induced structural joint damage is mediated by IL-1. Proc Natl Acad Sci U S A (2007) 1.61
Engagement of fatty acids with Toll-like receptor 2 drives interleukin-1β production via the ASC/caspase 1 pathway in monosodium urate monohydrate crystal-induced gouty arthritis. Arthritis Rheum (2010) 1.52
The role of interleukin-1 and the inflammasome in gout: implications for therapy. Arthritis Rheum (2007) 1.39
The pathogenesis of bone erosions in gouty arthritis. Ann Rheum Dis (2010) 1.34
Treating gout with pegloticase, a PEGylated urate oxidase, provides insight into the importance of uric acid as an antioxidant in vivo. Proc Natl Acad Sci U S A (2010) 1.23
Canakinumab. MAbs (2010) 1.16
Effect of prophylaxis on gout flares after the initiation of urate-lowering therapy: analysis of data from three phase III trials. Clin Ther (2010) 1.09
Determinants of the clinical outcomes of gout during the first year of urate-lowering therapy. Nucleosides Nucleotides Nucleic Acids (2008) 0.99
Canakinumab relieves symptoms of acute flares and improves health-related quality of life in patients with difficult-to-treat Gouty Arthritis by suppressing inflammation: results of a randomized, dose-ranging study. Arthritis Res Ther (2011) 0.95
Prevalence of comorbid conditions and prescription medication use among patients with gout and hyperuricemia in a managed care setting. J Clin Rheumatol (2004) 0.93
Anakinra's efficacy is variable in refractory gout: report of ten cases. Semin Arthritis Rheum (2010) 0.86
Resolution of gouty tophi after twelve weeks of pegloticase treatment. Arthritis Rheum (2008) 0.85
What do I need to know about gout? J Fam Pract (2010) 0.83